According to the Zephyr-database, which record investments in biotech start-up’s worldwide, the overall investments in biotech are increasing. This is the only good new, stated Gunter Festel, a VC-investor. There are however several bad news items.
Apparently, investments in start-up’s overall are decreasing. The capital is more likely to be invested in ‘older’ companies (older than 3 years). Another bad news item: the majority of these funds are being deployed in de US and in Asia. Europe is lagging behind, severely.
‘The question is: why?’, Festel stated. ‘To me, it is not a question of lack of money, but more of viable start-up’s that are able to bridge the technology gap (the route from technology to market).’